ABSTRACT
This article aims to analyze, from a legal perspective, the boundaries of the obligation imposed on health care providers to inform the patient. This requirement originated and was developed as an ethical issue. However, with the newly approved law regulating the rights and duties of patients, the obligation to inform can be viewed from prisms and principles that differ from those governing medical ethics. With this purpose, we will focus on the comparative experience, which will allow us to evaluate the responsibility of health care providers when this duty is breached. We will try to answer the following questions: Which medical information must be informed to the patient? When should the doctor inform the patient? In which form should this information be provided?.
Subject(s)
Humans , Informed Consent/legislation & jurisprudence , Moral Obligations , Patient Education as Topic/legislation & jurisprudence , Physician-Patient Relations , Consent Forms/legislation & jurisprudence , Patient Rights/legislation & jurisprudenceABSTRACT
Se presenta investigación documental realizada en 2009 que pretende documentar el marco normativo y los programas vigentes para la detección temprana del cáncer mamario en América Latina y establecer los retos más importantes para contener la epidemia en la región. Se identificaron diversas iniciativas emprendidas por las autoridades gubernamentales de salud para contrarrestar el crecimiento de la morbi-mortalidad por esta causa mediante estrategias de detección temprana, atención e investigación. A pesar de los avances en el diseño de políticas, programas, protocolos y guías de manejo clínico, persisten importantes retos para lograr los objetivos propuestos y la contención de este problema.
Documentary research carried out in 2009 aims to document the regulatory framework and existing programs for the early detection of breast cancer in Latin America and the Caribbean in order to establish the most important challenges for the containment of the epidemic in the region. The governments of the region have developed diverse efforts and initiatives to confront the rise in mortality due to said cause, including early detection, treatment and research strategies. Despite advances in the early detection of breast cancer, the challenge remains to link efforts to ensure continuity of care (diagnostic confirmation, treatment and monitoring) in order to achieve higher efficiency, effectiveness and benefits for women with this disease.
Subject(s)
Female , Humans , Breast Neoplasms/diagnosis , Early Diagnosis , Government Programs/statistics & numerical data , Health Policy , Breast Neoplasms/epidemiology , Breast Self-Examination , Caribbean Region/epidemiology , Clinical Protocols , Forecasting , Government Programs/legislation & jurisprudence , Government Programs/organization & administration , Government Publications as Topic , Health Promotion/legislation & jurisprudence , Health Promotion/methods , Health Promotion/statistics & numerical data , Latin America/epidemiology , Mammography , Mass Screening/legislation & jurisprudence , Mass Screening/organization & administration , Mass Screening/statistics & numerical data , Patient Education as Topic/legislation & jurisprudence , Patient Education as Topic/methods , Patient Education as Topic/statistics & numerical data , Women's Health Services/legislation & jurisprudenceABSTRACT
As bulas representam a principal fonte de informação escrita fornecida aos pacientes, especialmente aos idosos. O presente trabalho visou analisar o conteúdo das bulas dos medicamentos frequentemente prescritos para idosos com hipertensão, bem como a sua adequação à regulamentação sanitária e possíveis implicações para a saúde. Foi realizado um estudo descritivo em duas etapas: etapa A, em julho de 2002, e B em julho de 2007. Em cada etapa foram analisadas 34 bulas de sete fármacos anti-hipertensivos que constam na Relação Nacional de Medicamentos Essenciais (2006). Entre as 68 bulas analisadas, a maioria não continha todas as informações exigidas pela Portaria n° 110/1997 na etapa A (89,5 por cento) e pela RDC n°140/2003 na B (100 por cento). Alguns itens importantes como via de administração, modo de uso e superdose não constavam em 76 por cento das bulas analisadas. A falta dessas informações é relevante para a segurança dos pacientes. Com base nos dados obtidos, foi possível constatar o não cumprimento da legislação vigente nas duas etapas do estudo. Logo, é necessária maior atuação da Anvisa para assegurar o uso racional dos medicamentos e a redução dos riscos à saúde dos idosos.
The medication leaflets represent the main source of written information supplied to the patients, in special to the elderly. This study aimed to analyze the content of the leaflets of drugs often prescribed for elderly people with hypertension, as well as their adequacy to the sanitary regulations and possible health implications. A descriptive study was conducted in two stages: A, in July 2002, and B, in July 2007. In each stage were analyzed 34 medication leaflets of seven antihypertensive drugs of the National Essential Drugs List (2006). Among the 68 leaflets analyzed, most did not contain all the information required by Portaria nº 110/1997 (89.5 percent) in the stage A and the RDC nº 140/2003 (100 percent) in B. In 100 percent of the leaflets, the legislation had not been fulfilled. Some important topics as way of administration, how to use and overdose had been absent in 76 percent of the leaflets, the lack of this information has an impact in the security of the antihypertensive users. Based on these data, it was possible to evidence inadequate contents of the medication leaflets. So, it is necessary greater surveillance by Anvisa, to ensure the rational use of medicines and the reduction of the risks to the elderly health.